US-based biopharmaceutical company Ligand has reported positive data from two Phase I trials reports of LGD-6972 to treat type 2 diabetes.
LGD-6972 is Ligand’s glucagon receptor antagonist, which activates a non-insulin mechanism to lower plasma glucose in type 2 diabetic patients.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The Phase Ia and Phase Ib trials were designed as single and multiple-dose, randomised, double-blind and placebo-controlled studies to determine the safety, tolerability and pharmacokinetics profile of LGD-6972 when administered to healthy subjects and patients with type 2 diabetes mellitus.
LGD-6972 was administered in single or multiple oral doses.
Results indicated the efficacy of the glucagon receptor antagonist in lowering fasting plasma glucose within both the healthy subjects and type 2 diabetes patients, recording an increase in insulin and a decrease in glucagon responding to an oral glucose load.
The study data also suggested the safety and tolerability of LGD-6972, recording no dose-dependent changes in hematology, clinical chemistry or urinalysis panels, electrocardiography or vital signs and no hypoglycemic event.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataLigand CEO John Higgins said: “These clinical results are encouraging as they demonstrate a favourable safety profile for LGD-6972 and show a robust glycemic response in both healthy subjects and subjects with diabetes."
The company is planning to start a Phase II trial to demonstrate additional safety and efficacy data of LGD-6972.
The trial will be designed as a randomised, double-blind, multicentre study and include 148 patients whose blood glucose levels are inadequately controlled with metformin.
